follistatin
Follistatin, explained.
Follistatin is a naturally occurring protein studied for its role in blocking myostatin and activin A — two signals that normally limit muscle growth. This page is a neutral overview of what follistatin is, how it is described to work in research, and its regulatory status.
Educational only — not medical advice. Consult a qualified licensed provider.
Follistatin is a naturally occurring glycoprotein that binds myostatin and activin A — two signals that normally limit muscle growth. In animal and gene-therapy studies it has been investigated for its effect on muscle mass. The injectable 'Follistatin-344' sold to consumers is research-only, unproven in humans, and not FDA-approved.
What follistatin is
Follistatin is a protein your body already makes — a secreted glycoprotein found throughout the system, not a short synthetic peptide. Despite being grouped with peptides in muscle-building circles, the commonly referenced FST-344 form is a full 344-amino-acid glycoprotein weighing roughly 37.8 kDa. Its claim to fame is acting as a high-affinity blocker of myostatin (also called GDF-8) and activin A, two members of the TGF-β family that normally keep skeletal muscle from growing without limit. Several isoforms exist; the FST-344 version is notable because, after processing, it circulates through the bloodstream rather than staying bound to cell surfaces, giving it body-wide reach. In research, follistatin shows up two very different ways: as an AAV gene therapy actually tested in patients, and as a recombinant protein sold non-clinically for muscle goals. Those two are not the same thing, and only the gene-therapy form has produced real human data.
How follistatin works
Myostatin and activin A act as two of the body's brakes on muscle. Myostatin signals muscle to stop growing past a set point; activin A operates in a similar direction through the same receptor pathway. Follistatin binds both of them and neutralizes them, reducing that inhibitory signaling. Because it binds two limiters rather than one, research describes a larger effect than blocking myostatin alone — in transgenic animals engineered to block both signals, reported muscle-mass increases of roughly 194 to 327 percent compare with about 100 percent for knocking out myostatin alone. Mechanically, soaking up these ligands reduces downstream SMAD2/3 signaling, the pathway that normally restrains hypertrophy. Researchers note that activin has broad roles — reproductive, inflammatory, and fibrotic — so strong, systemic follistatin activity carries off-target potential that is poorly mapped outside of disease gene-therapy trials. And because a large glycoprotein is fragile, an injected version may not behave like the gene-expressed form studied in trials.
Areas of research interest
- Muscle mass and hypertrophy — the most-studied area, based on animal and gene-overexpression results
- Muscular dystrophy — investigated via AAV gene therapy, where the early human functional data exists (e.g. Becker MD)
- Inclusion-body myositis — another gene-therapy research context, with reported early functional changes in small trials
- Body composition — extrapolated and anecdotal interest only, not established in humans
- Myostatin inhibition biology — how blocking two signals (myostatin and activin) differs mechanistically from blocking one
Safety & legal status
The honest safety picture is thin: broad activin blockade has poorly characterized consequences across reproduction, inflammation, and fibrosis; myostatin and activin pathways are tumor-suppressive in some tissues, so long-term systemic blockade carries a theoretical proliferation concern that is not adequately studied; and researchers note that rapid changes in muscle mass could in principle outpace tendon and connective-tissue adaptation. Sourcing risk is severe — a large glycoprotein is hard to make and easy to mislabel, so the product often is not what the label claims. None of this is medical advice; talk to a qualified clinician about your own situation. On the legal side, follistatin is not FDA-approved for any general use — its only legitimate human research is as investigational AAV gene therapy in clinical trials, while the recombinant 'Follistatin-344' sold for muscle gain is a research chemical, not for human use, and myostatin inhibitors are banned in sport by WADA.
Follistatin vs IGF-1 LR3
| Follistatin | IGF-1 LR3 | |
|---|---|---|
| Core mechanism | Removes growth inhibition (blocks myostatin + activin A) | Adds growth signaling via the IGF-1 receptor |
| Molecule type | Large ~37.8 kDa glycoprotein (344 aa) | Modified IGF-1 peptide analog |
| Touches the GH axis? | No — independent of GH/IGF-1 | Acts directly on IGF-1 signaling |
| Human efficacy data | Only via gene therapy in disease trials; injectable unproven | Limited; largely anecdotal for muscle use |
| Approval status | Not FDA-approved; research-only | Not FDA-approved; research-only |
How PepEasy helps
Learn it
Get clear, cited, evidence-graded answers about follistatin — what it is, how it interacts with myostatin and activin, what the animal and gene-therapy research actually showed, and why the injectable form is unproven and unapproved.
Stay grounded
PepEasy is an educational reference — it organizes the science and points you to qualified providers. It does not recommend, sell, or tell you how to use any peptide.
Frequently asked
What does follistatin research look at?+
In research, follistatin is studied mainly for its binding of myostatin and activin A and the resulting effect on muscle mass in animals and gene-therapy models. Genuine human data comes only from investigational AAV gene therapy in disease trials, not from injecting the recombinant protein. This is educational information, not medical advice or a recommendation to use it.
What are follistatin's reported side effects?+
Because there is no controlled human injectable data, the risk picture described in the literature is largely theoretical: off-target activin blockade (reproductive, inflammatory, fibrotic roles) and a possible long-term proliferation concern, since these pathways are tumor-suppressive in some tissues. Sourcing risk is also noted — product is often mislabeled or inactive. This is not medical advice; consult a qualified licensed provider.
Is follistatin a steroid?+
No. Follistatin is a naturally occurring glycoprotein, not an anabolic steroid. It is studied for binding the proteins that limit muscle growth (myostatin and activin) rather than acting on androgen receptors. It is loosely called a peptide but is actually a large 344-amino-acid protein, and myostatin inhibitors are banned in sport by WADA.
Is follistatin FDA approved?+
No. As of 2026 follistatin is not FDA-approved for any general use. Its only legitimate human research exists as investigational AAV gene therapy in clinical trials, which is not commercially available. The recombinant 'Follistatin-344' sold for muscle gain is a research chemical, not for human use.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more